-
- ¹Úµ¿¼ö
-
- ¼Ò ¼Ó: ºñ´¢±â°ú, Àü¸³¼±¼¾ÅÍ
- Àü¹®ºÐ¾ß : Àü¸³¼±, ½ÅÀå, ¹æ±¤, °íȯ, Ç×¾ÏÄ¡·á, ±ÙÄ¡¼ö¼ú, ·Îº¿¼ö¼ú, ºê¶óÅ°
- Á÷ À§: ±³¼ö
- ¸Þ ÀÏ: ·Îº¿¼ö¼ú
- Àü È: 1577-4488
- ÆÑ ½º: ·Îº¿¼ö¼ú
- ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßž·Î 59
- ȨÆäÀÌÁö: https://blog.naver.com/doctor_park
ÅǸ޴º
¹øÈ£ | ±¸ºÐ | Á¦¸ñ |
---|---|---|
22 | (±¹³»)±âŸ | ½Å¼¼Æ÷¾ÏÀÇ ÀÚ°¡ µ¿Á¾ Á¾¾ç¼¼Æ÷ ¹× µ¿Á¾ ¶Ç´Â °ø¿©ÀÚ ¼öÁö»ó¼¼Æ÷ È¥ÇÕ¹é½ÅÀÇ °³¹ß ¹× Àû¿ë |
21 | (±¹³»)±âŸ | ±Þ¼º½Å¿ì½Å¿° ȯÀÚÀÇ ´Ù±â°ü Ư¼ººñ±³ |
20 | (±¹³»)±âŸ | Pneumatic Lithotriptor¸¦ ÀÌ¿ëÇÑ ¿ä°ü°æÇÏ ¹è¼®¼ú: 274·Ê ºÐ¼® |
19 | (±¹³»)SCIE | Evaluation of Short Term Clinical Effects and Presumptive Mechanism of Botulinum Toxin Type A as a Treatment Modality of Benign Prostatic Hyperplasia |
18 | (±¹³»)±âŸ | Chlormadinone Acetate°¡ Àü¸³¼±ºñ´ëÁõ ȯÀÚÀÇ Ç÷û Àü¸³¼±Æ¯ÀÌÇ׿øÄ¡¿¡ ¹ÌÄ¡´Â ¿µÇâ |
17 | (±¹³»)KCI | ¹Úµ¿¼ö, ¿Àµµ¿¬, °¸í¼, ¾ÈÈñÁ¤, À̼±ÁÖ, ±è³²±Ù: ÀüÀ̼º ½Å¼¼Æ÷¾ÏÀÇ º¸Á¶ ¸é¿ªÄ¡·á·Î½á ÀÚ°¡Á¾¾ç¹é½ÅÀÇ Àû¿ë |
16 | (±¹³»)SCOPUS | ÇϺοä·ÎÁõ»óÀ» º¸ÀÌ´Â Àü¸³¼±ºñ´ëÁõ¿¡¼ Àü¸³¼± ³» Botulinum Toxin Type A (BTA) ÁÖÀÔ¿ä¹ýÀÇ Ãʱâ°æÇè°ú °æ¿äµµÀû Àü¸³¼±ÀýÁ¦¼ú°úÀÇ ´Ü±âÈ¿°ú ºñ±³ |
15 | (±¹³»)SCOPUS | Ãæ¼öµ¹±â¸¦ ÀÌ¿ëÇÑ Èĺ¹¸·° ºÎ½Å°æÀýÁ¾¿¡ ÀÇÇÑ ¿ä°ü °á¼ÕÀÇ ´ëÄ¡ |
14 | (±¹³»)SCOPUS | Àü¸³¼± »ý°ËÀ» ¿äÇϴ ȯÀÚ¿¡¼ Àü¸³¼±¾Ï ¿¹Ãø Åë°è ¸ðµ¨ÀÇ °³¹ß |
13 | (±¹¿Ü)SCI | Expanded PolytetrafluoroethyleneÀ» ÀÌ¿ëÇÑ ½Å¿øº¸Á¸ ¼ö¼ú |
Copyright ¨Ï chamc, All rights reserved.